References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2020-21-144-150

medsovet-5978

Research Article

ГАСТРОЭНТЕРОЛОГИЯ

GASTROENTEROLOGY

Уникальный штамм Вifidobacterium longum и его эффективность при синдроме раздраженного кишечника

Unique strain of Bifidobacterium longum and its efficacy in irritable bowel syndrome

https://orcid.org/0000-0002-6150-1808

Плотникова

Е. Ю.

Plotnikova

E. Yu.

д.м.н., профессор кафедры поликлинической терапии, постдипломной подготовки врачей и сестринского дела, руководитель курса клинической гастроэнтерологии,

650022, Кемерово, ул. Ворошилова, д. 22а

22a, Voroshilov St., Kemerovo, 650029

eka-pl@rambler.ru

Кемеровский государственный медицинский университетРоссияKemerovo State Medical UniversityRussian Federation

2020

15012021

021144150

2021

Плотникова Е.Ю.

Plotnikova E.Y.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/5978

Синдром раздраженного кишечника является одним из самых распространенных желудочно-кишечных заболеваний во всем мире, поражающим от 5 до 15% взрослого населения в целом. На протяжении многих лет измененная моторика, висцеральная гиперчувствительность, иммунные изменения и, как выяснено с недавних пор, нарушенная функция эпителиального барьера были призваны объяснить происхождение симптомов при СРК. Сегодня пришло понимание того, что СРК заслуживает серьезного клинического и научного изучения. Совсем недавно были расширены связи между кишечником и мозгом, чтобы включить нового участника – микробиоту, что привело к созданию концепции оси «микробиота – кишка – мозг».

Микробиота является фактором риска возникновения синдрома раздраженного кишечника. Пробиотики, определяемые как живые микроорганизмы, могут изменять кишечную флору и регулировать функции кишечника, такие как снижение висцеральной гиперчувствительности, улучшение барьерной функции слизистой оболочки, модулировать иммунитет и хроническое воспаление, влиять на центральную нервную систему, воздействовать на моторику желудочно-кишечного тракта и т. п. Правильность этого подхода подтверждает ряд исследований пробиотика Bifidobacterium longum subsp. longum 35624, широко используемого в лечении симптомов синдрома раздраженного кишечника. Биологически активная добавка Bifidobacterium longum subsp. longum 35624 содержит 1 × 109 колониеобразующих единиц, что обеспечивает клинически эффективный уровень этих полезных бактерий. Bifidobacterium longum subsp. longum 35624 также уменьшает воспаление в желудочно-кишечном тракте и продемонстрировал положительные результаты в отношении уменьшения абдоминальных симптомов (например, боль/дискомфорт в животе и вздутие живота), связанных с синдромом раздраженного кишечника и другими состояниями.

Irritable bowel syndrome (IBS) is one of the most prevalent gastrointestinal disorders affecting between 5 and 15% of the general adult population worldwide. Over the course of many years altered intestinal motility, visceral hypersensitivity, immune changes and, as it has recently been found, impaired epithelial barrier function were meant to explain the origin of symptoms in the IBS. We have come to realize now that the IBS warrants serious clinical and scientific study. Not that long ago, the connections between the gut and the brain have been expanded to include a new entrant, the microbiota, resulting in the creation of a new concept of a microbiota-gut-brain axis.

Microbiota is a risk factor for the irritable bowel syndrome. Probiotics are defined as live microorganisms, which can alter the intestinal flora and regulate intestinal functions such as reduction of visceral hypersensitivity, improvement of mucosal barrier function, modulate immune responses and chronic inflammation, affect the central nervous system, gastrointestinal motility, etc. The correctness of this approach is confirmed by several studies of the probiotic Bifidobacterium longum subsp. longum 35624, which is widely used in the treatment of symptoms of irritable bowel syndrome. The dietary supplement Bifidobacterium longum subsp. longum 35624 contains 1 × 109 colony-forming units, which provides a clinically effective level of these beneficial bacteria. Bifidobacterium longum subsp. longum 35624 also reduces inflammation in the gastrointestinal tract and has positive results in reducing abdominal symptoms (e.g. abdominal pain / discomfort and bloating) associated with the irritable bowel syndrome and other conditions.

микробиотасиндром раздраженного кишечникаBifidobacterium longum subsp. longum 35624ось «кишка – мозг»

microbiotairritable bowel syndromeBifidobacterium longum subsp. longum 35624gut-brain axis

References1

Choung R.S., Locke G.R. Epidemiology of IBS. Gastroenterol Clin North Am. 2011;40(1):1–10. doi: 10.1016/j.gtc.2010.12.006.

Clarke G., Quigley E.M., Cryan J.F., Dinan T.G. Irritable bowel syndrome: towards biomarker identification. Trends Mol Med. 2009;15(10):478–489. doi: 10.1016/j.molmed.2009.08.001.

Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491. doi: 10.1053/j.gastro.2005.11.061.

Quigley E.M., Abdel-Hamid H., Barbara G., Bhatia S.J., Boeckxstaens G., De Giorgio R. et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol. 2012;46(5):356–366. doi: 10.1097/MCG.0b013e318247157c.

Quigley E.M. Bugs on the brain; brain in the gut – seeking explanations for common gastrointestinal symptoms. Ir J Med Sci. 2013;182(1):1–6. doi: 10.1007/s11845-012-0865-y.

Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721. doi: 10.1016/j.cgh.2012.02.029.

Sperber A.D., Drossman D.A., Quigley E.M. The global perspective on irritable bowel syndrome: A Rome Foundation-World Gastroenterology Organization symposium. Am J Gastroenterol. 2012;107(11):1602–1609. doi: 10.1038/ajg.2012.106.

Sperber A.D., Videlock E.J., Chang L. Irritable Bowel Syndrome. In: Podolsky D.K., Camilleri M., Fitz J.G., Kalloo A.N., Shanahan F., Wang T.C. (eds.). Yamada’s Textbook of Gastroenterology. 6th ed. USA: John Wiley & Sons Ltd.; 2016, pp. 1495–1521.

Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16)00222-5. doi: 10.1053/j.gastro.2016.02.031.

Quigley E.M. The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). J Clin Med. 2018;7(1):6. doi: 10.3390/ jcm7010006.

Banks W.A. Evidence for a cholecystokinin gut-brain axis with modulation by bombesin. Peptides. 1980;1(4):347–351. doi: 10.1016/0196-9781(80)90013-3.

Meguid M.M., Yang Z.J., Gleason J.R. The gut-brain brain-gut axis in anorexia: Toward an understanding of food intake regulation. Nutrition. 1996;12(1S):57–62. doi: 10.1016/0899-9007(95)00083-6.

Omran Y., Aziz Q. The brain-gut axis in health and disease. Adv Exp Med Biol. 2014;817:135–153. doi: 10.1007/978-1-4939-0897-4_6.

Rapps N., van Oudenhove L., Enck P., Aziz Q. Brain imaging of visceral functions in healthy volunteers and IBS patients. J Psychosom Res. 2008;64(6):599–604. doi: 10.1016/j.jpsychores.2008.02.018.

Mayer E.A., Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011;62:381–396. doi: 10.1146/annurev-med-012309-103958.

Mayer E.A., Gupta A., Kilpatrick L.A., Hong J.Y. Imaging brain mechanisms in chronic visceral pain. Pain. 2015;156(1 Suppl.):50-63. doi: 10.1097/j.pain.0000000000000106.

Guarner F., Malagelada J.R. Gut flora in health and disease. Lancet. 2003;361(9356):512–519. doi: 10.1016/S0140-6736(03)12489-0.

Codling C., O’Mahony L., Shanahan F., Quigley E.M., Marchesi J.R. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. 2010;55(2):392–397. doi: 10.1007/s10620-009-0934-x.

Jeffery I.B., Quigley E.M., Öhman L., Simrén M., O’Toole P.W. The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes. 2012;3(6):572–576. doi: 10.4161/gmic.21772.

Quigley E.M. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin North Am. 2011;40(1):207–222. doi: 10.1016/j.gtc.2010.12.009.

Yarandi S.S., Peterson D.A., Treisman G.J., Moran T.H., Pasricha P.J. Modulatory effects of gut microbiota on the central nervous system: How the gut could play a role in neuropsychiatric health and disease. J Neurogastroenterol Motil. 2016;22(2):201–212. doi: 10.5056/jnm15146.

Quigley E.M. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep. 2017;17(12):94. doi: 10.1007/s11910-017-0802-6.

De Palma G., Collins S.M., Bercik P., Verdu E.F. The microbiota-gut-brain axis in gastrointestinal disorders: Stressed bugs, stressed brain, or both? J Physiol. 2014;592(14):2989–2997. doi: 10.1113/jphysiol.2014.273995.

Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M. et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042–1054. doi: 10.1053/j.gastro.2016.12.039.

Liu H.N., Wu H., Chen Y.Z., Chen Y.J., Shen X.Z., Liu T.T. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017;49(4):331–337. doi: 10.1016/j.dld.2017.01.142.

Tap J., Derrien M., Törnblom H., Brazeilles R., Cools-Portier S., Doré J. et al. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology. 2017;152(1):111–123. doi: 10.1053/j.gastro.2016.09.049.

Bennet S.M.P., Böhn L., Störsrud S., Liljebo T., Collin L., Lindfors P. et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut. 2018;67(5):872–881. doi: 10.1136/gutjnl-2016-313128.

Ford A.C., Spiegel B.M., Talley N.J., Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–1286. doi: 10.1016/j.cgh.2009.06.031.

Ghoshal U.C., Gwee K.A. Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: The missing link. Nat Rev Gastroenterol Hepatol. 2017;14(7):435–441. doi: 10.1038/nrgastro.2017.37.

Barbara G., Feinle-Bisset C., Ghoshal U.C., Quigley E.M., Santos J., Vanner S. et al. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016;S0016–5085(16):00219–5. doi: 10.1053/j.gastro.2016.02.028.

Wu J.C. Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths? Gastroenterol Hepatol. 2010;6(11):705–711. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033541.

Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L. et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35–37. doi: 10.1038/nm1521.

Mangell P., Nejdfors P., Wang M., Ahrné S., Weström B., Thorlacius H., Jeppsson B. Lactobacillus plantarum 299 v inhibits Escherichia coliinduced intestinal permeability. Dig Dis Sci. 2002;4(3):511–516. doi: 10.1023/a:1017947531536.

Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B. et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126(2):520–528. doi: 10.1053/j.gastro.2003.11.019.

Quigley E.M. Microflora modulation of motility. J Neurogastroenterol Motil. 2011;17(2):140–147. doi: 10.5056/jnm.2011.17.2.140.

Butel M.J. Probiotics, gut microbiota and health. Med Mal Infect. 2014;44(1):1–8. doi: 10.1016/j.medmal.2013.10.002.

Song K.H., Jung H.K., Kim H.J., Koo H.S., Kwon Y.H., Shin H.D. et al. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24(2):197–215. doi: 10.5056/jnm17145.

Hungin A.P.S., Mitchell C.R., Whorwell P., Mulligan C., Cole O., Agréus L. et al. Systematic review: probiotics in the management of lower gastrointesti nal symptoms – an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018;47(8):1054–1070. doi: 10.1111/apt.14539.

Liang D., Longgui N., Guoqiang Xu. Efficacy of different probiotic protocols in irritable bowel syndrome A network meta-analysis. Medicine (Baltimore). 2019;98(27):e16068. doi: 10.1097/MD.0000000000016068.

Quigley E.M. Probiotics in Irritable Bowel Syndrome: The Science and the Evidence. J Clin Gastroenterol. 2015;49 S1:S60–S64. doi: 10.1097/MCG.0000000000000348.

Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus ststement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi: 10.1038/nrgastro.2014.66.

Altmann F., Kosma P., O’Callaghan A., Leahy S., Bottacini F., Molloy E. et al. Genome analysis and characterisation of the exopolysaccharide produced by Bifidobacterium longum subsp. longum 35624. PLoS One. 2016;11(9):e0162983. doi: 10.1371/journal.pone.0162983.

Schiavi E., Gleinser M., Molloy E., Groeger D., Frei R., Ferstl R. et al. The surface-associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses. Appl Environ Microbiol. 2016;82(24):7185–7196. doi: 10.1128/AEM.02238-16.

Giron F., Quigley E.M. Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. J Neurogastroenterol Motil. 2018;24(3):355–366. doi: 10.5056/jnm18004.

Dunne C., O’Mahony L., Murphy L., Thornton G., Morrissey D., O’Halloran S. et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr. 2001;73(2S):386s–392s. doi: 10.1093/ajcn/73.2.386s.

Charbonneau D., Gibb R.D., Quigley E.M. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4(3):201–211. doi: 10.4161/gmic.24196.

Collins J.K., Dunne C., Murphy L., Morissey D. O’Mahony L., O’Sullivan E. et al. A Randomised controlled trial of a probiotic Lactobacillus strain in healthy adults: assessment of its delivery, transit and influence on microbial flora and enteric immunity. Microb Ecol Health Dis. 2002;14(2):81–89. doi: 10.1080/08910600260081720.

Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62. doi: 10.1186/s12876-016-0470-z.

Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033–1049. doi: 10.1038/ ajg.2009.25.

Yuan F., Ni H., Asche C.V., Kim M., Walayat S., Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191–1197. doi: 10.1080/03007995.2017.1292230.

Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O’Mahony L. et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–1590. doi: 10.1111/j.1572-0241.2006.00734.x.

O’Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K. et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–551. doi: 10.1053/j.gastro.2004.11.050.

Groeger D., O’Mahony L., Murphy E.F., Bourke J.F., Dinan T.G., Kiely B. et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–339. doi: 10.4161/gmic.25487.

Konieczna P., Akdis C., Quigley E., Shanahan F., O’Mahony L. Portrait of an immunoregulatory bifidobacterium. Gut Microbes. 2012;3(3):261–266. doi: 10.4161/gmic.20358.

McKernan D.P., Fitzgerald P., Dinan T.G., Cryan J.F. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil. 2010;22(9):1029–35. doi: 10.1111/j.1365-2982.2010.01520.x.

Konieczna P., Groeger D., Ziegler M., Frei R., Ferstl R., Shanahan F. et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: Potential role for myeloid and plasmacytoid dendritic cells. Gut. 2012;61(3):354–366. doi: 10.1136/gutjnl-2011-300936.

Wall R., Cryan J.F., Ross R.P., Fitzgerald G.F., Dinan T.G., Stanton C. Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biology. 2014;817:221–239. doi: 10.1007/978-1-4939-0897-4_10.

Coates M.D., Mahoney C.R., Linden D.R., Chen J., Blaszyk H., Crowell M.D. et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126(7):1657–1664. doi: 10.1053/j.gastro.2004.03.013.

Desbonnet L., Garrett L., Clarke G., Bienenstock J., Dinan T.G. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008;43(2):164–174. doi: 10.1016/j.jpsychires.2008.03.009.

Rahimi R., Nikfar S., Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci. 2008;4(1):71–76.

Yano J.M., Yu K., Donaldson G.P., Shastri G.G., Ann P., Ma L. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–276. doi: 10.1016/j.cell.2015.02.047.

Guarner F., Sanders M.E., Eliakim R., Fedorak R., Gangl A., Garisch J. et al. Probiotics and prebiotics. 2017. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-2017.pdf.

The authors declare that there are no conflicts of interest present.